Clinical Significance of Circulating Tumor Cells in Unresectable Pancreatic Ductal Adenocarcinomas

Background: Circulating tumour cells (CTCs) have emerged as liquid biopsy biomarker providing non-invasive assessment of cancer progression and biology. We investigated whether longitudinal analysis of CTCs could monitor disease progression, response to chemotherapy, and survival in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Methods: CTCs were isolated using a centrifugal microfluidic disc from serially collected peripheral blood with clinical assessments. CTCs were enumerated with immunostaining against Epithelial cell adhesion molecule, Cytokeratin, Plectin-1 and CD45. Results: CTCs were detected in 92.3% of 52 patients with unresectable PDAC at the time of diagnosis. CTC numbers were not statistically different across tumour sizes, stages and metastatic sites. The absolute CTC counts after chemotherapy was inversely related to survival, and the decreased number of CTCs after the first cycle of chemotherapy was significantly associated with longer survival. Conclusions: Identifying CTCs and monitoring CTC changes after chemotherapy could be a useful prognostic marker for survivals in patients with unresectable PDACs. Funding: This work was supported by a grant from SK Chemical Research Fund of the Korean Society of Gastroenterology (Grant No.800 20130378) and a grant from Korean Gastroenterology Fund for Future Development. This study was granted by the Korean Health Technology R&D Project, Ministry of Health & Welfare funded by the Korean Government (Grant No. HI12C1845) HI12C1845), and work by Y.K.Cho was partially supported by IBS R020 D1 funded by the Korean Government. This research was supported by Collaborative Genome Program for Fostering New Post Genome industry through the National Research Foundation (NRF) funded by the Korean governnment (MSIT) (Grant No. NRF-2017M3C9A5031002), and also supported by National Research Foundation (NRF) grant funded by the Korean government (MSIT) (Grant No. 2019R1C1C1008646). Clinical Trial Registration ID #: NCT02934984

is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the most common cancer with lethal effects, and the overwhelming majority of patients with PDAC have a locally advanced or distant metastatic disease (80-85%) (1,2). It is currently the fourth leading cause of cancer-related deaths in the United States and is projected to be the second most common cause by 2030 (3). Despite many efforts to improve survival, it is still a lethal disease with a 5-year survival rate of less than 5% and a median survival of less than 1 year (4). The reasons for such poor survival are the lack of symptoms and effective ways to screen for pancreatic cancer, which result in a delayed detection of cancer (5). The computed tomography (CT) scan and endoscopic ultrasound (EUS)guided biopsy become classic tool for the diagnosis with pathology confirmation of unresectable PDACs. Thus, there are clinical unmet needs for biomarker either tissue based or liquid biopsy to monitor and predict its prognosis in unresectable PDACs, especially. EUS-guided fine needle aspiration/biopsy (FNA/B) is still considered an invasive procedure; hence, it is unfit to use for monitoring disease progression and detecting molecular genetic changes during the courses of treatment. There have been many investigations to find biomarkers for PDAC and CA19-9 is, so far, the only biomarker with somewhat clinical usefulness. It is used for therapeutic monitoring and early detection of recurrent disease after treatment in pancreatic cancer (6,7). However, it is not a specific biomarker to pancreatic cancer; CA19-9 level is also elevated in other conditions like cholestasis, lung diseases and other malignancy as well. In addition, approximately 10% of patients with PDACs who are negative for Lewis antigen a or b cannot synthesize CA19-9 (8).
Circulating tumour cells (CTCs) are rare, viable, tumour-derived epithelial cells . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint 6 identified in the peripheral blood of patients with cancer, which accompany tumour invasion into the blood. The ability to detect and analyse these CTCs in PDAC may give us insights into its aggressive biology (9,10). Several studies have focused on identifying CTCs in the blood for diagnosis, staging and prognostication for various cancers (11)(12)(13). There have been studies in other tumour models, such as lung, breast, and prostate cancers that suggest that the presence of CTCs in the peripheral circulation of patients with metastatic carcinoma is associated with shorter survival (14)(15)(16). Unfortunately, there are only a few studies about the detection of CTCs in PDAC.
Multiple strategies for CTC isolation and identification have been reported (17)(18)(19); however, there have been emerging problems due to the extreme rarity, short lifetime and heterogeneity of CTCs. For example, antigen-dependent capture using an epithelial marker, Epithelial cell adhesion molecule (EpCAM), is a common isolation method, which can overlook CTCs undergoing an epithelial-to-mesenchymal transition (EMT) (20). Therefore, we additionally utilised a PDAC-specific marker, Plectin-1, to detect CTCs from patients with PDAC. Plectin-1 is known as a novel biomarker for primary and metastatic PDAC. It was identified in 100% of invasive PDAC tumours and 60% of pre-invasive Pancreatic intraepithelial neoplasia (PanIN) III lesions and was retained in metastatic deposits. Moreover, Plectin-1 distinguished PDAC from benign inflammatory diseases, like chronic pancreatitis (21). Recently, we have reported that captured PDAC CTCs were confirmed using Plectin-1 detection antibody as well as EpCAM antibody with KRAS mutation (22). Here, we examined whether Plectin-1 combined with EpCAM could improve CTC detection and the Plectin-1 positive PDAC CTCs can be used as prognostic biomarkers. The aims of this study . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

EpCAM, CK and Plectin-1 for CTC detection
EpCAM and CK are often overexpressed by epithelial carcinoma cells such as lung, colorectal, breast, prostate, head and neck, and liver, but absent in hematologic cells.
Therefore, typical CTC enumeration method relies on the positive immunostaining of EpCAM and CK. While EpCAM has been widely used for immunospecific capture of CTCs from unfractionated blood, it cannot capture the CTCs under the epithelialmesenchymal transition (20). We first confirmed the expression of EpCAM and CK in human pancreatic cancer cell lines by flow cytometry to determine if these antigens would be suitable for enumeration of PDAC CTCs. Pancreatic cancer cell lines, except PANC1 and Mia-PaCa2, abundantly expressed EpCAM on their surfaces ( Figure 1A).
In addition, all pancreatic cancer cell lines expressed the CK antigens, mostly at very high levels ( Figure 1B). In these EpCAM/CK-expressing cells, these antigens were uniformly expressed throughout the entire population whereas WBCs did not express these antigens (Figure 1A and B).
In addition, we tested Plectin-1, a novel PDAC-specific biomarker reported to be expressed on the membrane and cytoplasm of PDAC cells (21). We could find out that all PDAC cell lines expressed the Plectin-1 antigen and it was uniformly expressed throughout the entire population, whereas WBCs rarely express this antigen ( Figure   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint 8 1C). Moreover, immunoblot analysis showed the expression of EpCAM, CK and Plectin-1 in pancreatic cancer cells but not in WBCs ( Figure 1D). Also, we observed an intensive expression of Plectin-1 in ductal cancer cells of the PDAC tissue except WBCs through IHC staining ( Figure 1E). Plectin-1 was thoroughly expressed in the metastatic liver tissue from PDAC patients as well, whereas its expression was very low in normal pancreas tissue and immune cells in palatine tonsil or intestine tissue (Supplementary Figure 1). We previously reported that healthy subjects had negligible CTC counts (mean, 0 CTCs/7.5 mL; median, 0 CTCs/7.5 mL; range, 0−5 CTCs/7.5mL of blood) when EpCAM and CK antibodies were used to detect CTCs (23,24). Recently, we have also showed the specificity of Plectin-1 to capture CTCs in PDAC (22). In twenty-eight blood samples (3ml/each) from healthy donors, there was . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Enrichment and identification of CTCs in patients with PDAC
PDAC CTCs were enriched using 'FAST disc', a centrifugal microfluidic tangential flow filtration device, which allowed rapid, label-free isolation of CTCs from whole blood . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint without sample pre-treatment (24). First, the membrane of FAST disc was examined after running the blood samples of PDAC patients by haematoxylin and eosin (H&E) staining (Figure 2A). We found CTCs captured on the membrane, which was further confirmed as cancer cells by specialized pathologists.
Next, we performed molecular characterization of the cells captured on the membrane of the FAST disc. KRAS mutation is the most frequently detected somatic alteration in PDACs (nearly 100%) (25) and thus the detection of KRAS mutants can be a proof to confirm that the captured cells are CTCs of PDACs. After the enrichment of CTCs from the blood samples of patients with PDAC, DNAs were extracted from the cells captured on the membrane and followed by ddPCR. Three types of KRAS mutant (G12D, G12V, G12R) were detected in CTCs from patients with PDAC ( Figure 2D and Supplementary Figure 3A). AsPC-1 was used as a positive control for PDAC, which had KRAS G12D mutant. Moreover, we picked single Plectin-1 + cell (Supplementary Figure 3B) and confirmed KRAS G12D mutant (a single CTC isolated from patient #1), which was also detected from the sample prepared from the whole membrane capturing CTCs (Figure 2D).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Baseline characteristics of study patients
A total of 52 patients were enrolled in this study, and their baseline characteristics are described in Table 1. There were 26 male and 26 female patients aged 46-85 years . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint (median 67 years). Clinical stage (8 th AJCC) was as follows: 21 were stage III (40.4%) and 31 were stage IV (59.6%). Twenty patients (38.5%) had metastasis to the liver, and 11 patients (21.1%) showed metastasis to bone, peritoneum and supraclavicular lymph node (SCN) without liver. The 46 patients (88.5%) received chemotherapy and 6 patients (11.5%) did not receive chemotherapy due to patient preference, old age or poor performance status. Median (range) of initial CA19-9 and CEA were 203.5 IU/ml (3.75-140000 IU/ml) and 2.9 ng/mL (0.5-51.39 ng/mL), respectively.  Figure 3A). In addition, CTC counts were remarkably higher in stage III than IV (*p=0.0403, Figure 3B). The most common site of metastasis is the liver in PDAC due to the fact that the first venous drainage of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint 14 pancreatic cancer is the portal circulation. There was no significant difference in the number of CTCs across the metastatic sites (p=0.077), but patients having multimetastases to the liver and other sites, such as the peritoneum, lung, bone and SCN had increased CTC counts (Figure 3C).

Assessment of CTC numbers before and after chemotherapy
CTCs were evaluated in patients who underwent chemotherapy (CTx). Blood samples were collected at baseline (pre-CTx) and during subsequent clinic visits for treatment (post-CTx). We could collect full series of blood draws both pre-CTx and post-CTx from thirty-nine patients according to the performance status. The exact follow-up schedule varied between patients. CT scan and serum CA19-9 measurement were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint performed at baseline and at regular intervals according to standard clinical practice ( Figure 4A). Upon comparing CTC counts in pre-and post-CTx blood samples of patients with PDAC, we found that the absolute number of CTCs was not remarkably decreased after treatment (p=0.5496, Figure 4B). There was no significant difference in CTC counts at baseline according to tumour location (p=0.3970, Figure 4C); however, CTC counts were higher in head PDAC than body/tail PDAC after treatment (*p=0.0253, Figure 4D). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint respectively). Each bar represents the median. CT, computed tomography; CA19-9, carbohydrate antigen 19-9. In addition, absolute CTC counts at post-CTx (*p=0.0471) could predict survival of patients with PDAC in which the number of CTCs over the median (47.5/3 ml blood) at post-CTx was associated with worse prognosis. However, this correlation was not observed with pre-CTx counts (p=0.3088) (Figure 5A and 5B).

Clinical significance of CTC changes after chemotherapy
We calculated the change in CTC numbers after chemotherapy relative to the number of CTCs at baseline, and we evaluated its relationship with chemotherapy responses and OS of patients with PDAC. A higher CTC count at post-CTx compared to pre-CTx was more evident in patients who poorly responded to the treatment (stable disease is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint statistical significance (Figure 6A). Absolute numbers of CTC were significantly elevated in the increased CTC group of patients with PDAC after chemotherapy (*p=0.0208, Figure 6B). Furthermore, the Kaplan-Meier analysis indicated that patients who had relatively increased CTCs after chemotherapy showed worse prognosis ( Figure 6C). The OS was longer when the number of CTCs were reduced after chemotherapy, and patients with PDAC with an increase of CTCs showed shorter survival (median OS, 16.97 vs. 10.02 months; **p=0.0095). The association of CA19-9 changes with patient survival was also examined as CA19-9 is the most commonly used biomarker for diagnosis and management of patients with pancreatic cancer (26).
The increase or decrease of CA19-9 level with chemotherapy failed to prognose the survival of patients with PDAC ( Figure 6D).

Figure 6. Evaluation of CTC changes after chemotherapy in patients with PDAC
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint The change of CTC numbers after chemotherapy (post-CTx) relative to before chemotherapy (pre-CTx) was evaluated with chemotherapy responses and overall survival (OS) of patients with PDAC. (A) The relative change of CTC counts was assessed with responses to chemotherapy in patients with PDAC.
There was no significance between the completely or partially responded (CR/PR) group and stably or progressively responded (SD/PD) group (p=0.1561). (B) The number of CTCs was compared between patients with increased CTCs (increased CTC group) and patients with decreased CTCs (decreased CTC group) after chemotherapy (*p=0.0208). Each bar represents the median. Kaplan-Meier survival curve was stratified by the comparative changes (increased or decreased) of (C) CTC counts and (D) serum CA19-9 levels after chemotherapy. Significance was observed in the change of CTC numbers (**p=0.0095), but not in the change of CA19-9 levels (P=0.8210).

Investigation into CTCs may give us insights on the biology of tumour cell dissemination in patients with cancer. Little is known about the biology and pathology
of CTCs in PDAC due to difficulty in collecting them in the peripheral circulation. Here we efficiently collected CTCs from blood samples of patients with PDAC by using sizebased centrifugal microfluidic disc and by using both EpCAM, CK, and Plectin-1 identification antibodies to estimate their prognostic potential for responses to treatment and survival.
Tumour cells in the peripheral blood are substantially heterogeneous, which offers a unique opportunity to understand how CTCs participate in the tumour dissemination process and tumour heterogeneity (10). However, these heterogeneous properties of rare CTCs make it harder to detect their variable phenotypes in circulation. The only system currently approved by the Food and Drug Administration (FDA) as an aid in monitoring patients with metastatic breast, colorectal or prostate cancer is CELLSEARCH® (Janssen Diagnostics, Raritan, NJ, UA), which uses . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint antibodies specific to EpCAM and CK of epithelial CTCs (18). However, CTCs exhibit dynamic changes in epithelial and mesenchymal compositions (27), and show both epithelial and mesenchymal features (28). They can show no or low expression of EpCAM during EMT, resulting in missed detection (29). Furthermore, EpCAM is downregulated in pancreatic cancer (30,31). To make up for this, we decided to use a PDAC-specific antibody in addition to EpCAM and CK. The ideal biomarker for PDAC should not only differentiate benign conditions from malignancy but also be able to detect small cancers, ideally at the pre-invasive PanIN III phase. Plectin-1 expression is positive in all PDACs but negative in benign tissues. Moreover, it could detect preinvasive PanIN III lesions (21). Therefore, we additionally utilised a PDAC biomarker, Plectin-1, to identify CTCs in the peripheral blood samples of patients with PDAC. As a result, we were able to successfully detect cells positive to only Plectin-1 and not EpCAM/CK in the bloodstream (Figure 2B). Moreover, KRAS mutant was detected in both Plectin-1 + cells and CTCs captured on the membrane (Figure 2D). Thus, PDAC CTCs were defined as all EpCAM/CK orPlectin-1-positive cells in our study ( Figure   2C). CTC enumeration with an additional Plectin-1 antibody could more significantly predict OS compared to CTC enumeration with only EpCAM/CK antibodies (**p=0.0095 vs. *p=0.0152, HR=2.971 vs. HR=2.689, Figure 6C and Supplementary   Figure 4).
The enumeration of CTCs was not statistically different in relation to tumour size and metastatic sites (Figure 3A and B). Patients with stage III PDAC showed more CTCs than patients with stage IV PDAC (Figure 3B). CTCs mediate the metastatic dissemination of cancer (32), and can be expected to include the subpopulations responsible for disease progression (10). Seventy-three percentage . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint of patients with stage III PDAC showed poor responses, and it is likely that the high number of CTCs could mean the potential of progression. It is worth further investigation.
Our study was designed such that CTCs were identified both before and after chemotherapy with the clinical assessment of the CT scan and serum CA19-9 measurement (Figure 4A). The number of CTCs was not significantly decreased by chemotherapy across all patients with PDAC ( Figure 4B). The detection and existence of CTCs can be a key model of haematogenous spread in the development of metastatic disease. The existence of CTCs expressing the cell surface EpCAM and intracellular CKs is related to poor outcome in patients with both non-metastatic and metastatic disease (33)(34)(35). In our result, patients with PDAC with a high number of CTCs showed worse prognosis, but CTC counts had prognostic value for survival prediction only at post-CTx and not at pre-CTx (Figure 5A and 5B). Furthermore, the relative change between pre-CTx and post-CTx has more critical prognostic significance to predict the probability of survival. Patients with decreased CTCs after chemotherapy indicated a significantly longer survival, whereas patients with increased CTCs showed poor survival ( Figure 6C and Supplementary Figure 5).
However, it seems that the evaluation of both absolute CTC counts and relative CTC changes with chemotherapy is not enough to predict chemotherapy responses ( Figure   6A). Considering that the blood collection was only performed after the first cycle of the treatment, there is a need for further investigation to reveal the association of CTC counts with poor (SD/PD) or good (CR/PR) responses to chemotherapy.
The sensitivity of CTC capture and identification was 91.8% in our results, which is higher than other reports. Sefrioui et al reported 67% sensitivity of CTC in . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021 (37). Serum level of CA19-9 is the only marker approved by the United States FDA for use in the routine management of pancreatic cancer (38,39). The sensitivity of CA19-9 is 63.6%, and changes in serum levels are unrelated to disease progression (30). It coincided with a result where an increased or decreased level of CA19-9 with chemotherapy was not related to the probability of survival (Figure 6D) as opposed to significant correlation of CTC changes with survival ( Figure 6C).
The direction of systemic cancer treatment based on the primary tumour characteristics has limitations due to the tumour heterogeneity and frequent discrepancy between primary and metastatic sites. However, because of both inaccessibility of metastatic sites and procedure morbidity, metastatic biopsies are rarely undertaken (40,41). In this sense, the prognostic role of CTC enumeration is the true promise to provide a real-time view of cancer progression just using peripheral blood samples, avoiding the need for repeat invasive biopsies. Understanding the biology of CTCs or cancer cells in transit may give us unique insights into the mechanisms behind metastasis. In addition, further genomic analysis of CTCs needs to be performed.

Validation of Capture and Identification Antibodies
Pancreatic cancer cell lines were maintained as a monolayer in culture media including

Microfluidic Approach to Isolate and Enumerate CTCs
The CD-PRIME TM system of the CD-CTC disposable disc and CD-CTC Enrichment kit (Clinomics, Inc., Ulsan, Korea) was used to isolate CTCs efficiently from millions of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint other blood cells in whole blood samples. This CTC enrichment system called 'Fluid-Assisted Separation Technology (FAST) disc' is based on centrifugal microfluidic separation (23,24,42). This device was previously reported by our group, and the After washing with the 1% BSA solution 3 times, CTCs captured on the disc membrane were fixed with 4% paraformaldehyde for 15 min at room temperature for the next CTC staining and enumeration processes.

Staining and enumeration of CTCs
CTCs fixed on the membrane were immunostained using the CD-CTC cell (1:100). All antibodies, including pan CK, EpCAM and CD45 antibodies, were included . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Confirmation of KRAS Mutation in Captured CTCs
After CTC enrichment from the blood of PDAC patients, DNA was recovered from the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The relative change of CTCs between pre-CTx and post-CTx (increased or decreased) was evaluated with overall survival of PDAC patients (**p=0.0097).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.      Figure 3-source data 1. All dataset for enrolled 52 patients A total of 52 patients with PDAC was enrolled, and their clinical information and CTC counts were collected. The first sheet includes data for a total of 52 patients, and the second sheet includes data for 39 patients with paired CTC counts after chemotherapy.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256283 doi: medRxiv preprint